| Document |
Document Title |
|
WO/2022/220613A1 |
The present invention relates to a novel method for preparing a compound of chemical formula 7, or a salt thereof, which is disclosed in the present specification and can be effectively used as a sphingosine-1-phosphate receptor agonist.
|
|
WO/2022/220611A1 |
The present invention relates to a novel method for preparing a compound represented by formula 5 or a salt thereof set forth in the present specification, wherein the compound or salt can be used as a sphingosine-1-phosphate receptor ag...
|
|
WO/2022/221493A1 |
Described herein are novel piperidine urea derived compounds and their pharmaceutical compositions for the treatment of conditions and diseases mediated by soluble epoxide hydrolase.
|
|
WO/2022/220600A1 |
The present invention relates to a crystalline form of a sphingosine-1-phosphate receptor agonist and, more particularly, to a crystalline form of 1-[1-chloro-6-(3-chloro-1-isopropyl-1H-indazol-5-ylmethoxy)-
3,4-dihydro-naphthalen-2-ylme...
|
|
WO/2022/220601A1 |
The present invention relates to a pharmaceutically acceptable salt of a sphingosine-1-phosphate receptor agonist and a crystalline form thereof, and more specifically, to a potassium salt or methanesulfonate of 1-[1-chloro-6-(3-chloro-1...
|
|
WO/2022/219412A1 |
Disclosed herein, in part, is a compound or pharmaceutically acceptable salts or stereoisomers thereof of formula I: (I) wherein X1 is selected from the group consisting of linear or branched C1-6 alkyl, C3-6 cycloalkyl, C6-10 aryl, 5-10...
|
|
WO/2022/218429A1 |
The present application relates to a bicyclic substituted aromatic carboxylic acid compound, and in particular to a compound as represented by formula (I) and a pharmaceutically acceptable salt thereof. In formula (I), R2 and R3 and atom...
|
|
WO/2022/218247A1 |
Provided are a deuterated compound as a CDK4/6 inhibitor, a preparation method therefor, a pharmaceutical composition comprising a deuterated compound, and a use thereof. Compared with a non-deuterated reference compound, the present inv...
|
|
WO/2022/218442A1 |
Disclosed are a ring-modified proline short peptide compound and the use thereof, and specifically disclosed is a compound represented by formula (x) or a pharmaceutically acceptable salt thereof.
|
|
WO/2022/221181A1 |
The present invention relates to compounds represented by Formulae (I) to (V), or a racemate, enantiomer, diastereomer, pharmaceutically acceptable salt, solvate, hydrate, or derivative thereof, and compositions thereof. In various aspec...
|
|
WO/2022/221673A1 |
Bifunctional compounds, which find utility as modulators of B-cell lymphoma 6 protein (BCL6; target protein), are described herein. In particular, the bifunctional compounds of the present disclosure contain on one end a cereblon ligand ...
|
|
WO/2022/221526A1 |
Disclosed are compounds of formulae (I) - (IV), and pharmaceutically acceptable salts thereof, which are inhibitors of kallikrein-related peptidase 5 (KLK5). Also provided are pharmaceutical compositions comprising such a compound, and m...
|
|
WO/2022/221519A1 |
Described herein are compositions, uses thereof, and methods for treating a viral infection in a host cell or organism infected by the virus, such as coronaviruses, Zika virus, Lassa virus, Crimean Congo hemorrhagic fever virus, hepatiti...
|
|
WO/2022/219546A1 |
The present application relates to Leukotriene A4 hydrolase (LTA4H) inhibitors of formula (I), for use in the treatment of various disorders.
|
|
WO/2022/221686A1 |
The disclosure provides compounds with warheads and their use in treating medical diseases or disorders, such as viral infections. Pharmaceutical compositions and methods of making various compounds with warheads are provided. The compou...
|
|
WO/2022/219146A2 |
Compounds of formula (I) wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts stereoisomers, enantiomers, tautomers and N-oxides of those compounds, can be used as insecticides.
|
|
WO/2022/216947A1 |
Provided herein are certain isoindolinone compounds and imaging agents useful for detecting a disease or condition associated with protein aggregation, compositions thereof, and methods of their use.
|
|
WO/2022/217008A1 |
The present disclosure encompasses solid state forms of Zavegepant, in embodiments crystalline polymorphs of Zavegepant, processes for preparation thereof, and pharmaceutical compositions thereof.
|
|
WO/2022/215034A1 |
The present invention relates to Poly(ADP-ribose) polymerase (PARP) inhibitors, methods of preparing them, pharmaceutical compositions containing them and to their use in methods of treatment and/or prevention of PARP mediated diseases o...
|
|
WO/2022/216097A1 |
The present invention relates to: a novel leucine-rich repeat kinase 2 (LRRK2) inhibitor of chemical formula 1; a pharmaceutical composition containing same for preventing or treating LRRK2-mediated or -related diseases or disorders; and...
|
|
WO/2022/217295A1 |
Described are compounds of formula (I), or pharmaceutically acceptable salts thereof: (I) that are useful for control of protein expression with eDHFR tags and methods of controlling protein expression with such compounds, as well as kit...
|
|
WO/2022/214701A1 |
Kinase-targeted covalent inhibitors are usually irreversibly targeting noncatalytic cysteines in the ATP- binding site. These compounds are designed by directly introducing an electrophile on a reversible-inhibitor scaffold. Our inventio...
|
|
WO/2022/216573A1 |
Disclosed are compounds of Formula (I) or a salt thereof, wherein R1, R2, R3, R4, Z, m, n, p, and q are defined herein. Also disclosed are methods of using such compounds to inhibit Helios protein, and pharmaceutical compositions compris...
|
|
WO/2022/216094A1 |
The present invention relates to: a novel compound having excellent GLP-1 agonist activity and an excellent DMPK profile, and thus useful as an agent for treating or preventing obesity or various metabolic diseases such as diabetes and h...
|
|
WO/2022/214702A1 |
Our invention relates to novel triazine compounds, containing chemical reactive groups (warheads) and behaving as reversible and irreversible covalent inhibitors. Linkers have been introduced to target a solvent exposed, distal cysteine ...
|
|
WO/2022/216975A1 |
Disclosed herein are compounds, such as compounds of Formulae (I), (II), and (III), and d3-etoricoxib, and pharmaceutically acceptable salts, hydrates, solvates, polymorphs, co- crystals, metabolites, and prodrugs thereof, and compositio...
|
|
WO/2022/216709A1 |
This disclosure is directed, at least in part, to GPR119 agonists useful for the treatment of conditions or disorders involving the gut-brain axis. In some embodiments, the GPR119 agonists are gut-restricted compounds. In some embodiment...
|
|
WO/2022/214106A1 |
Disclosed are a naphthyl urea compound having anti-cancer effect, a preparation method therefor, and a use thereof. The naphthalene urea parent nucleus radical group contained therein having biological activity is further chemically modi...
|
|
WO/2022/214008A1 |
A compound having a structure of formula (I) or formula (II) and having the activity of inhibiting HPK1 kinase and a pharmaceutical composition comprising said compound and a use thereof in the prevention and/or treatment of cancer, tumo...
|
|
WO/2022/214606A1 |
The present invention relates to compounds of formula (I) or salts, solvates, cocrystals, tautomers, or mixtures thereof. Furthermore, the present invention relates to pharmaceutical compositions comprising said compounds. Moreover, the ...
|
|
WO/2022/216655A1 |
The present invention relates to (6-((octahydrocyclopenta[c]pyrrol-5- yl)amino)pyridazin-3-yl)benzamide (R2b is -C(O)N(RA1)(RA2) and N- (6-((octahydrocyclopenta[c]pyrrol-5-yl)amino)pyridazin-3-yl)
phenyl) carboxamide (R2b is -N(RB)C(O)R...
|
|
WO/2022/216098A1 |
The present invention relates to: a novel leucine-rich repeat kinase 2 (LRRK2) inhibitor of chemical formula 1; a pharmaceutical composition for the prevention or treatment of diseases or disorders mediated by or associated with LRRK2, t...
|
|
WO/2022/216644A1 |
Disclosed are compounds of Formula (I): or a salt thereof, wherein R1, R2, R4, R6, m, and n are defined herein. Also disclosed are methods of using such compounds to inhibit Helios protein, and pharmaceutical compositions comprising such...
|
|
WO/2022/214921A1 |
The present invention relates to an improved process for the preparation of intermediate compounds used in the preparation of Antihistamine agents. The present invention specifically relates to an improved process for the preparation of ...
|
|
WO/2022/216626A1 |
Described herein are hydroxypyridine HSD17B13 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of liver disease, metabolic disease, or cardiovascul...
|
|
WO/2022/214044A1 |
Disclosed are compounds as represented by formulas (A) to (D) or pharmaceutically acceptable salts, stereoisomers, solvates or prodrugs thereof, the definitions of the groups in the formulas being detailed in the description. Further dis...
|
|
WO/2022/207482A1 |
The present invention relates to compounds of Formula (I), or an agronomically acceptable salt of said compounds wherein X, Y1, Y2, R1, R2, R7, and n are as defined herein. The invention further relates to herbicidal compositions which c...
|
|
WO/2022/212296A1 |
A compound of Formula (I), (I'), (II), (II'), (III), or (IV) or a pharmaceutically-acceptable salt thereof, is described, wherein the substituents are as defined herein. Pharmaceutical compositions comprising the same and method of using...
|
|
WO/2022/206684A1 |
Provided are a series of Se-containing pyrazine compounds and an application thereof. Specifically disclosed are a compound represented by formula (I) and a pharmaceutically acceptable salt thereof.
|
|
WO/2022/207752A1 |
A compound comprising the formula (I), wherein each X1 is independently selected from C, N, O and S; each Y is independently selected from C and N; Z1 is independently selected from C and N; each X1 may independently be unsubstituted, or...
|
|
WO/2022/205587A1 |
Disclosed in embodiments of the present invention are an organic compound and a production method therefor, and a display panel. The general formula of the organic compound is (I), wherein Ar includes any one of or a combination of some ...
|
|
WO/2022/206797A1 |
Compounds of formula A, a method for using said compounds as an EGFR inhibitor, and a pharmaceutical composition comprising said compounds. The compounds can be used to treat, prevent or ameliorate diseases or conditions such as cancers ...
|
|
WO/2022/212818A1 |
Described are 6-aryl [1,2,4]triazolo[4,3-a]pyridin-3(2H)-ones as negative allosteric modulators of metabotropic glutamate receptor 2 (mGlu2), pharmaceutical compositions including the compounds, and methods of using the compounds and com...
|
|
WO/2022/212489A1 |
Described herein are MK2 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of autoimmune disorders, chronic inflammatory disorders, acute inflammato...
|
|
WO/2022/212707A1 |
The present invention relates to antiviral agents according to Formula (I) and their use in the treatment of viral infection.
|
|
WO/2022/212194A1 |
Compounds of formula (I), wherein the variable substituents are defined herein.
|
|
WO/2022/210524A1 |
The present invention addresses the problem of providing a nitrogen-containing compound effective for inhibiting cancer stem cell proliferation.　This problem is solved by a nitrogen-containing compound represented by general formula (I...
|
|
WO/2022/206939A1 |
Provided is a heterocyclic compound serving as an FGFR inhibitor, and specifically, disclosed are a compound represented by formula (I), and a stereoisomer or pharmaceutically acceptable salt thereof.
|
|
WO/2022/208454A1 |
The present disclosure relates to novel N2-phenylpyrimidine-2,4-diamine compounds, method for preparing the same, and pharmaceutical composition or health functional food for the prevention or treatment of cancer, containing the same as ...
|
|
WO/2022/208382A1 |
The present invention provides a compound of chemical formula 1, a compound of chemical formula 3, compound [212], compound [224], or compound [228], a pharmaceutically acceptable salt thereof, a stereoisomer thereof, a hydrate thereof, ...
|
